Home Biosimilar Antibodies Immunology & Inflammation CD markers Elotuzumab (anti-SLAMF7)
For research use only. Not for use in humans.

Elotuzumab (anti-SLAMF7)

Synonyms: CS1， CD319

Elotuzumab (anti-SLAMF7, BMS-901608, PDL063, HuLuc63) is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell–mediated antibody-dependent cellular cytotoxicity.

Elotuzumab (anti-SLAMF7)

Click to purchase the isotype control of Elotuzumab (anti-SLAMF7)

3 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 10.96 mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Elotuzumab (anti-SLAMF7, BMS-901608, PDL063, HuLuc63) is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell–mediated antibody-dependent cellular cytotoxicity.
References

Product Details

CAS No. 915296-00-3
Molecular Weight 145 kD
Isotype Human IgG1, κ
Source CHO cells
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05730036 RECRUITING Drug: Linvoseltamab|Drug: Elotuzumab|Drug: Pomalidomide|Drug Relapsed Refractory Multiple Myeloma (RRMM) Regeneron Pharmaceuticals 2023-09-18 PHASE3
NCT06785415 RECRUITING Drug: Dexamethasone|Drug: Iberdomide Recurrent Multiple Myeloma Mayo Clinic 2025-03-18 PHASE1; PHASE2
NCT06518551 RECRUITING Drug: Elotuzumab|Drug: Iberdomide|Drug: Dexamethasone Myeloma; Multiple Myeloma; Refractory Multiple Myeloma Omar Nadeem, MD 2024-11-01 PHASE1; PHASE2
NCT03948035 ACTIVE_NOT_RECRUITING Drug: Elotuzumab|Drug: Carfilzomib|Drug: Lenalidomide|Drug: Newly Diagnosed Multiple Myeloma Wuerzburg University Hospital 2018-08-28 PHASE3
NCT07555938 RECRUITING Drug: Cevostamab|Drug: Pomalidomide|Drug: Dexamethasone|Drug Multiple Myeloma Hoffmann-La Roche 2026-06-23 PHASE3
NCT04517851 ACTIVE_NOT_RECRUITING Myelofibrosis Transformation in Essential Thrombocythemia; Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Primary Myelofibrosis M.D. Anderson Cancer Center 2021-02-10 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-03-06)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.